Drug intelligence / Profile preview

CRx-191

Development stage: Phase 1
Lead developer: CombinatoRx
Modality: Small Molecules
Administration: Topical

Overview

CRx-191 is a proprietary synergistic combination drug candidate developed for topical treatment of plaque psoriasis and other steroid-responsive dermatoses. It was identified by CombinatoRx using a proprietary screening assay to discover novel drug combinations with enhanced inhibition of tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) release, both cytokines implicated in the pathogenesis of psoriasis. The drug demonstrated significant efficacy in Phase 2 clinical trials, showing marked reductions in psoriatic infiltrate and erythema compared to placebo. Despite promising results, development was discontinued after Phase 2[1][2][3][5].

Brand names: CRx-191CRx191CRx 191
Other names: mometasone furoate + nortriptyline hydrochloride

Targets

IFNG (Interferon gamma)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on CRx-191.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRx-191.

Explore the full profile